JP2017501977A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501977A5
JP2017501977A5 JP2016533067A JP2016533067A JP2017501977A5 JP 2017501977 A5 JP2017501977 A5 JP 2017501977A5 JP 2016533067 A JP2016533067 A JP 2016533067A JP 2016533067 A JP2016533067 A JP 2016533067A JP 2017501977 A5 JP2017501977 A5 JP 2017501977A5
Authority
JP
Japan
Prior art keywords
tgf
ligand
tgfbrii
receptor
capturer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016533067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501977A (ja
JP6640083B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066776 external-priority patent/WO2015077540A2/en
Publication of JP2017501977A publication Critical patent/JP2017501977A/ja
Publication of JP2017501977A5 publication Critical patent/JP2017501977A5/ja
Priority to JP2019233811A priority Critical patent/JP6952100B2/ja
Application granted granted Critical
Publication of JP6640083B2 publication Critical patent/JP6640083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016533067A 2013-11-21 2014-11-21 肺高血圧症を治療するための組成物および方法 Active JP6640083B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019233811A JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907260P 2013-11-21 2013-11-21
US61/907,260 2013-11-21
PCT/US2014/066776 WO2015077540A2 (en) 2013-11-21 2014-11-21 Compositions and methods for treating pulmonary hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233811A Division JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017501977A JP2017501977A (ja) 2017-01-19
JP2017501977A5 true JP2017501977A5 (cg-RX-API-DMAC7.html) 2018-04-05
JP6640083B2 JP6640083B2 (ja) 2020-02-05

Family

ID=53180397

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016533067A Active JP6640083B2 (ja) 2013-11-21 2014-11-21 肺高血圧症を治療するための組成物および方法
JP2019233811A Active JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法
JP2021156343A Active JP7474729B2 (ja) 2013-11-21 2021-09-27 肺高血圧症を治療するための組成物および方法
JP2024065676A Pending JP2024096891A (ja) 2013-11-21 2024-04-15 肺高血圧症を治療するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019233811A Active JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法
JP2021156343A Active JP7474729B2 (ja) 2013-11-21 2021-09-27 肺高血圧症を治療するための組成物および方法
JP2024065676A Pending JP2024096891A (ja) 2013-11-21 2024-04-15 肺高血圧症を治療するための組成物および方法

Country Status (9)

Country Link
US (3) US10682392B2 (cg-RX-API-DMAC7.html)
EP (4) EP4005585B1 (cg-RX-API-DMAC7.html)
JP (4) JP6640083B2 (cg-RX-API-DMAC7.html)
CN (2) CN105934249A (cg-RX-API-DMAC7.html)
AU (3) AU2014352843B2 (cg-RX-API-DMAC7.html)
CA (1) CA2931309C (cg-RX-API-DMAC7.html)
DK (2) DK3685848T3 (cg-RX-API-DMAC7.html)
ES (2) ES2902533T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015077540A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) * 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
AU2017336546C1 (en) * 2016-09-27 2025-05-29 Epicentrx, Inc. Immunomodulatory fusion proteins
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
FI3628049T3 (fi) 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
US11274142B2 (en) 2017-05-12 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-β receptor and medicinal uses thereof
AU2018338612A1 (en) 2017-09-27 2020-05-07 Epicentrx, Inc. Immunomodulatory fusion proteins
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
CN111867612B (zh) * 2018-03-26 2024-11-12 阿尔托生物科学有限责任公司 抗PDL1、IL-15和TGF-β受体组合分子
MX2021005018A (es) 2018-11-09 2021-06-15 Jiangsu Hengrui Medicine Co Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁(杭州)生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用
CN114173806A (zh) * 2019-07-26 2022-03-11 密歇根州立大学董事会 预防或治疗骨骼肌脂肪变性的方法
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
TW202128763A (zh) * 2019-11-12 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 含有TGF-β受體的融合蛋白及其醫藥用途
US20250152670A1 (en) * 2022-04-28 2025-05-15 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0975771B1 (en) * 1997-04-18 2007-07-11 Biogen Idec MA Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
AU4572899A (en) 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
AU2003273991A1 (en) * 2002-10-14 2004-05-04 Michelin Recherche Et Technique S.A. Extended mobility tyre comprising bead with symmetrical force distribution
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0514259D0 (en) 2005-07-12 2005-08-17 Renovo Ltd Pharmaceutical compositions
US20080009500A1 (en) * 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP2029625A2 (en) 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
CN100588717C (zh) 2007-03-21 2010-02-10 中国医学科学院阜外心血管病医院 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途
ATE520682T1 (de) 2007-08-22 2011-09-15 Irm Llc 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren
EP2037275A1 (en) 2007-09-11 2009-03-18 F. Hoffmann-La Roche AG Differentiation of different causes of right heart failure
KR101008385B1 (ko) 2008-08-01 2011-01-14 한국과학기술연구원 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
US20110172296A1 (en) 2010-01-12 2011-07-14 Bennett C Frank Modulation of transforming growth factor-beta 1 expression
EP2372364A1 (en) 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012093125A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
CN108341863A (zh) 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
CA2843535C (en) * 2011-08-01 2021-04-06 Tufts Medical Center, Inc. Treatment of cardiac diseases and fibrosis with endoglin receptor antibodies and antigen-binding fragments thereof
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
AU2013202269A1 (en) 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
CA2915627A1 (en) 2012-06-15 2013-12-19 The General Hospital Corporation Inhibitors of micrornas that regulate production of atrial natriuretic peptide (anp) as therapeutics and uses thereof
EP2597466A1 (en) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients
EP2900263B1 (en) 2012-09-26 2019-06-05 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
CN111100197B (zh) 2013-01-17 2024-11-15 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
KR101346132B1 (ko) 2013-02-18 2013-12-31 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14
KR101346181B1 (ko) 2013-02-18 2014-01-03 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) * 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
CN113817672A (zh) 2014-05-18 2021-12-21 儿童医学中心公司 涉及外排体的方法和组合物
CA2952061A1 (en) 2014-06-13 2015-12-17 Novartis Ag Use of serelaxin to reduce gdf-15
US20170137505A1 (en) 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders

Similar Documents

Publication Publication Date Title
JP2017501977A5 (cg-RX-API-DMAC7.html)
JP2008529558A5 (cg-RX-API-DMAC7.html)
JP2015517489A5 (cg-RX-API-DMAC7.html)
JP2016539946A5 (cg-RX-API-DMAC7.html)
JP2015514132A5 (cg-RX-API-DMAC7.html)
JP2008535800A5 (cg-RX-API-DMAC7.html)
JP2019511222A5 (cg-RX-API-DMAC7.html)
JP2016531144A5 (cg-RX-API-DMAC7.html)
JP2011530599A5 (cg-RX-API-DMAC7.html)
JP2013533858A5 (cg-RX-API-DMAC7.html)
JP2019031567A5 (cg-RX-API-DMAC7.html)
JP2015522576A5 (cg-RX-API-DMAC7.html)
JP2012115277A5 (cg-RX-API-DMAC7.html)
JP2019151636A5 (cg-RX-API-DMAC7.html)
JPWO2019107530A5 (cg-RX-API-DMAC7.html)
JP2016519062A5 (cg-RX-API-DMAC7.html)
JP2019531293A5 (cg-RX-API-DMAC7.html)
JP2016505635A5 (cg-RX-API-DMAC7.html)
JP2007500236A5 (cg-RX-API-DMAC7.html)
JP2012530761A5 (cg-RX-API-DMAC7.html)
JP2012526839A5 (cg-RX-API-DMAC7.html)
JP2016512213A5 (cg-RX-API-DMAC7.html)
JP2015110588A5 (cg-RX-API-DMAC7.html)
JP2017537084A5 (cg-RX-API-DMAC7.html)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze